Fig. 2. Tumorigenicity of CDDP-resistant EAC cells vs. parent EAC cells. A. The tumor growth progress displaying the differential tumorigenicity between the resistant and sensitive EAC cells. B. Two-way ANOVA analysis was done for tumor size on day 17. Data are expressed as mean ± SD. * p < 0.05, **p < 0.01, *** p < 0.001, ns: nonsignificant. EAC: Ehrlich ascites carcinoma, SEC: solid Ehrlich carcinoma, SEC-CDDP: SEC treated with cisplatin, SEC-indomethacin: SEC treated with indomethacin, SEC-combination: SEC treated with CDDP and indomethacin, SEC/CDDP: cisplatin-resistant SEC, SEC/CDDP-CDDP: cisplatin-resistant SEC treated with cisplatin, SEC/CDDP-indomethacin: cisplatin-resistant SEC treated with indomethacin, SEC/CDDP-combination: cisplatin-resistant SEC treated with CDDP and indomethacin.